Last updated: February 24, 2026
What is the Drug NDC 00054-0282?
NDC 00054-0282 is the formulation of epoetin alfa, marketed under the brand name Epogen. It is a recombinant human erythropoietin used to treat anemia caused by chronic kidney disease, chemotherapy, and certain surgical procedures. Epogen has been approved by the FDA since 1989.
Market Overview
Market Size and Demand Drivers
Epogen's annual US sales have fluctuated due to competition and policy changes, but it remains a significant player in anemia treatments. The global erythropoiesis-stimulating agent (ESA) market was valued at approximately USD 6 billion in 2022 and projected to reach USD 8 billion by 2027, growing at a compound annual growth rate (CAGR) of 6.2% (Market Research Future, 2022).
Major factors impacting demand include:
- Rising prevalence of chronic kidney disease (CKD), estimated to affect over 37 million adults in the US (CDC, 2020).
- Increasing use of ESA in oncology patients receiving chemotherapy.
- Evolving guidelines favoring anemia management with ESAs.
Competitive Landscape
Key competitors include:
- Darbepoetin alfa (Aranesp, Amgen)
- Methoxy polyethylene glycol-epoetin beta (Mircera, Roche)
- Biosimilar versions introduced in late 2010s, such as Epogen biosimilars, affecting market share.
Regulatory Environment
In 2019, the FDA reclassified ESAs as class II devices with specific REMS (Risk Evaluation and Mitigation Strategy) requirements due to safety concerns, notably increased risks of cardiovascular events at higher hemoglobin levels. Such policies influence prescribing behavior and market growth.
Patent and Patent Expiry
The original patent for Epogen expired in 2015 in the United States. While the original patent ended, patent protections for biosimilars are limited, with exclusivity periods varying by region.
Price Trends and Projections
Historical Pricing Data
The average wholesale price (AWP) for Epogen was around USD 300 per vial in 2015. After biosimilar entry in 2017-2018, prices declined by approximately 20-30%. As of 2022, the average price for a 200 mcg vial ranges from USD 200 to 250.
Current Price Dynamics
| Year |
Average Price per Vial (USD) |
Notes |
| 2015 |
300 |
Pre-biosimilar era |
| 2018 |
220 |
Biosimilar competition emerged |
| 2022 |
200–250 |
Stabilization after initial declines |
Future Price Projections (2023–2027)
Given biosimilar penetration and regulatory influences, prices are expected to stabilize or decline marginally. The projected trend suggests:
- 2023–2024: Prices remain near current levels, with slight reductions to USD 180–210 per vial as biosimilar use increases.
- 2025–2027: Prices may further decline to USD 160–180 per vial, driven by increased biosimilar adoption and payer negotiations.
Factors Influencing Future Prices
- Biosimilar market share: Biosimilars could command up to 60% of the ESA market within five years.
- Regulatory and policy changes: Potential adjustments to REMS or reimbursement policies could affect pricing.
- Manufacturing costs: Patent expirations reduce barriers to entry, pressuring prices downward.
Implications for Stakeholders
- Pharmaceutical Companies: Biosimilar entrants will leverage lower manufacturing costs for competitive pricing.
- Payers: Increased biosimilar adoption may lead to significant cost savings.
- Prescribers: Growing safety data and regulatory guidance influence prescribing patterns toward biosimilars.
Summary
| Aspect |
Data/Forecast |
| Market size (2022) |
USD 6 billion (Global ESA market) |
| CAGR (2022–2027) |
6.2% |
| Price (2022) |
USD 200–250 per vial |
| Projected price (2027) |
USD 160–180 per vial |
Key Takeaways
- Epogen remains a key product in anemia therapy, but biosimilars are diminishing its market share and pricing power.
- Current prices are declining due to biosimilar competition and increased market entry.
- Policy and regulatory environments continue to influence the market trajectory.
- The total market for ESAs is expected to grow, sustaining demand despite price reductions.
- Stakeholders should monitor biosimilar launches and policy shifts for strategic planning.
FAQs
1. What factors are driving the decline in Epogen prices?
Biosimilar entry, regulatory policies supporting cost savings, and payer negotiations reduce average wholesale prices.
2. How does biosimilar competition influence market share?
Biosimilars can capture up to 60% of the ESA market within five years, eroding the sales of branded products like Epogen.
3. Are there risks to the stability of future prices?
Yes. Policy changes, safety concerns, or manufacturing issues could disrupt price trends.
4. How do regulatory guidelines impact the ESA market?
The 2019 REMS program for ESAs restrict certain uses and require prescriber and distributor certification, affecting prescribing patterns and pricing.
5. What is the outlook for international markets?
Emerging markets show increasing adoption of biosimilars, expanding international competition and further pressure on prices.
References
- CDC. (2020). Chronic Kidney Disease Surveillance System. Centers for Disease Control and Prevention.
- Market Research Future. (2022). Global Erythropoiesis-Stimulating Agents Market Research Report.
- Food and Drug Administration. (2019). REMS Program for Erythropoiesis-Stimulating Agents.
